Not actual patient.
Not actual patient.
Cisplatin is a powerful medicine used to treat cancer. Over time, cisplatin builds up in the cochlea (cok-lee-ah), the spiral-shaped part of the inner ear.
*Based on Chang grading scale. Prevalence may differ based on alternate grading scales.
Cochlear damage can begin early and continue even after cisplatin treatment ends. A person may begin to not hear higher-pitched sounds like music or birds. Later, they may not hear lower-pitched sounds like thunder. That’s why it’s important they get their hearing tested before, during, and after treatment.
Symptoms and responses to any treatment may vary so it’s important to talk with a healthcare provider about what is the right treatment plan and to follow the doctor’s recommendations.
Adapted from Langer T, et al.
Most people who have non-metastatic cancer (cancer that has not spread) that are treated with cisplatin recover.
However, their hearing loss will last forever and impact almost every part of their life.
Speech and language skills
Social-emotional development
Academic performance
Career potential
Ability to live independently
Academic performance
Fennec HEARS™ is the single source for both financial and patient support. Call 1-833-7PEDMARK.
Find helpful tools and resources.
Please see full Prescribing Information, including Patient Information, for PEDMARK.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.
It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.
It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.